KLB, klotho beta, 152831

N. diseases: 53; N. variants: 6
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0028754
Disease: Obesity
Obesity
0.100 GeneticVariation disease BEFREE The G-allele frequency of <i>KLB</i> rs7674434 and T-allele frequency of rs12152703 were higher in the obese with NAFLD than obese without NAFLD group (<i>P</i> = 0.004 and <i>P</i> = 0.006), but the genotype distribution between two non-obese groups did not differ. 31548436 2019
CUI: C0028754
Disease: Obesity
Obesity
0.100 AlteredExpression disease BEFREE Since obesity has been reported to be associated with reduced expression of FGFR1 and βKlotho receptor in white adipose tissues in mice, our results suggest that the distribution in adipose tissues was influenced by target expression levels. 28895785 2018
CUI: C0028754
Disease: Obesity
Obesity
0.100 Biomarker disease BEFREE Replenishment of recombinant FGF21 to a level equivalent to that in obesity restores SAT mass and reverses insulin resistance in FGF21KO, but not in adipose-specific βklotho knockout mice. 29348470 2018
CUI: C0028754
Disease: Obesity
Obesity
0.100 AlteredExpression disease BEFREE KLB and FGFR1 were upregulated in AT in relation to obesity, and both were further increased 12 months after RYGB. 28552744 2017
CUI: C0028754
Disease: Obesity
Obesity
0.100 AlteredExpression disease BEFREE In WAT, overweight/obesity with and without type 2 diabetes led to reduced expression of KLB, but increased FGFR1c expression. 28721439 2017
CUI: C0028754
Disease: Obesity
Obesity
0.100 Biomarker disease BEFREE β-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue. 28422755 2017
CUI: C0028754
Disease: Obesity
Obesity
0.100 AlteredExpression disease BEFREE In addition to higher FGF21 levels, reduced KLB expression in liver and adipose tissue has been noted in these same individuals, suggesting that obesity may represent an FGF21 resistant state. 26901091 2016
CUI: C0028754
Disease: Obesity
Obesity
0.100 Biomarker disease BEFREE Recent microRNA (miR) studies have revealed that aberrantly elevated miR-34a in obesity directly targets β-Klotho, the obligate coreceptor for both FGF19 and FGF21, and attenuates metabolic signaling of these hormones. 27125742 2016
CUI: C0028754
Disease: Obesity
Obesity
0.100 Biomarker disease BEFREE However, further studies are needed to explore the possibility that Klotho could be a novel therapeutic target to reduce obesity and related complications, and to determine whether and how Klotho might influence the regulation and function of a related protein, β-Klotho, which is also involved in energy metabolism. 22641000 2012
CUI: C0028754
Disease: Obesity
Obesity
0.100 Biomarker disease BEFREE These results indicate that aberrantly elevated miR-34a in obesity attenuates hepatic FGF19 signaling by directly targeting βKL. 22988100 2012